Učitavanje...
Recent advances in theranostics and challenges for the future
Theranostic nuclear oncology is on the cusp of adoption into routine clinical management of neuroendocrine tumours (NETs) following publication of the Phase 3 randomised controlled trial, NETTER-1. For the first time, level 1b evidence of efficacy and safety of 68-gallium/177-lutetium-DOTA-octreotat...
Spremljeno u:
| Izdano u: | Br J Radiol |
|---|---|
| Glavni autor: | |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
The British Institute of Radiology.
2018
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6475948/ https://ncbi.nlm.nih.gov/pubmed/29565650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1259/bjr.20170893 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|